Arcus Biosciences, Inc. (RCUS)

NYSE: RCUS · Real-Time Price · USD
10.53
+0.05 (0.48%)
At close: Aug 22, 2025, 4:00 PM
10.53
0.00 (0.00%)
After-hours: Aug 22, 2025, 4:10 PM EDT
0.48%
Market Cap1.12B
Revenue (ttm)262.00M
Net Income (ttm)-298.00M
Shares Out 106.43M
EPS (ttm)-3.07
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume726,946
Open10.55
Previous Close10.48
Day's Range10.48 - 11.00
52-Week Range6.50 - 18.98
Beta0.89
AnalystsBuy
Price Target20.71 (+96.68%)
Earnings DateAug 6, 2025

About RCUS

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2α inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical tria... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 15, 2018
Employees 627
Stock Exchange NYSE
Ticker Symbol RCUS
Full Company Profile

Financial Performance

In 2024, Arcus Biosciences's revenue was $258.00 million, an increase of 120.51% compared to the previous year's $117.00 million. Losses were -$283.00 million, -7.82% less than in 2023.

Financial Statements

Analyst Summary

According to 8 analysts, the average rating for RCUS stock is "Buy." The 12-month stock price target is $20.71, which is an increase of 96.68% from the latest price.

Price Target
$20.71
(96.68% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient...

2 days ago - Business Wire

Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Uranium Energy Corp. UEC, saying, “I like nuclear.”

Other symbols: UEC
8 days ago - Benzinga

Arcus Biosciences: A Risky Buy Ahead Of Pivotal, Catalyst-Rich 12 Months

Arcus Biosciences is at a critical juncture, with multiple late-stage assets and a cash position nearly equal to its market cap. Casdatifan shows best-in-class potential in renal cell carcinoma, with ...

12 days ago - Seeking Alpha

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

16 days ago - Business Wire

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

4 weeks ago - Business Wire

Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

6 weeks ago - Business Wire

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

2 months ago - Business Wire

Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript

Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Pia Eaves - VP, IR Terry Rosen - CEO Richard Markus - CMO Jennifer Jarrett - COO Bob G...

3 months ago - Seeking Alpha

Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

3 months ago - Business Wire

Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

4 months ago - Business Wire

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient...

4 months ago - Business Wire

Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts

Arcus Biosciences presents a high-risk speculation with significant upcoming catalysts, despite recent stock declines and Gilead's exit from the ARC-10 trial. Gilead's continued investment and board p...

5 months ago - Seeking Alpha

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient...

6 months ago - Business Wire

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

6 months ago - Business Wire

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

6 months ago - Business Wire

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

6 months ago - Business Wire

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

6 months ago - Business Wire

Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

6 months ago - Business Wire

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

7 months ago - Business Wire

Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025

Arcus Biosciences has interesting combination therapies that target several diseases like NSCLC, RCC, GI, and pancreatic cancers. The company has a few ongoing Phase 3 trials, some of which will repor...

7 months ago - Seeking Alpha

Arcus: Excellent Pipeline And Collaborations, Cash Runway

Arcus Biosciences presents a strong buying opportunity due to positive data, Gilead's increased stake, and a robust pipeline with significant market potential. Lead molecule domvanalimab shows promisi...

7 months ago - Seeking Alpha

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient...

8 months ago - Business Wire

Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript

10 months ago - Seeking Alpha

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

10 months ago - Business Wire

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

10 months ago - Business Wire